STATEMENT: Aducanumab FDA Approval And Biogen’s Pricing Prove Urgent Need For Medicare Negotiation
“Today, we are watching our drug pricing system break under the weight of Medicare’s inability to negotiate lower drug prices."
“Today, we are watching our drug pricing system break under the weight of Medicare’s inability to negotiate lower drug prices."
Patients For Affordable Drugs (P4AD) released a new video today debunking Big Pharma’s myth that any limits on its unilateral power to dictate prices on brand-name drugs will kill innovation and new drug development.
The New York Times today published an op-ed by David Mitchell, cancer patient and founder of Patients For Affordable Drugs.
As The Fight To Lower Drug Prices Ramps Up, Audrey Baker Will Lead P4AD’s Communications Efforts
New Report Debunks Pharma's Claim That Any Restraint On Its Unilateral Pricing Power Will Destroy Innovation And Access To New Medicines.
Veteran Advocacy Leader Sheila McLean Takes The Helm At Critical Moment For Drug Pricing Reform.
Nearly 150 More Price Increases In Just The Last Two Weeks Bring Total To 783
Median price hike of 4.99 percent is more than four times the rate of inflation.
Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.